echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The seventh batch of national mining will open bids for nearly 200 pharmaceutical companies to enter the bureau

    The seventh batch of national mining will open bids for nearly 200 pharmaceutical companies to enter the bureau

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    01 The seventh batch of national mining will be opened soon

    According to the previous official documents of the seventh batch of national procurement, all provinces need to complete the review of relevant drug procurement requirements before 17:00 on February 25



    .

    The time has come to the 21st, and the review of the seventh batch of drug procurement requirements will be completed this week



    .

    The Hunan Provincial Medical Insurance Bureau stipulated in the "Notice on Submitting the Purchase Data Related to the Scope of the Seventh Batch of Nationally Organized Centralized Purchase of Drugs" that the review time of the county, city and state medical insurance departments is from February 17, 2022 to 2022 At 24:00 on February 21, 2019 (that is, today).

    According to the regular progress arrangement of procurement with volume, after the procurement demand is reviewed and reported, the stages of the announcement of the centralized procurement documents, the opening of the bid, the release of the proposed selection result, the confirmation of the official selection result and the landing time will be carried out.

     

    02 The injections are collected in a centralized manner, and the varieties are gradually comprehensive

    A total of 26 injections were included in the seventh batch of national procurement, accounting for about 50% of the total number of varieties collected this time



    .



    Except that the sixth batch of national procurement is special for insulin, the first five batches of national procurement are all involved in the field of chemical medicine, covering 218 varieties, and the number of injection varieties has reached more than 40



    .

    It is worth noting that in this collection, multiple injections are different dosage forms of the previous collection



    .

    For example, omeprazole enteric-coated capsules were selected in the third batch of national procurement, and omeprazole injection was included in this centralized procurement; in the fifth batch of national procurement, metoprolol oral normal release was selected.



    Dosage form, this time the collection of metoprolol sustained-release dosage form is included



    .

    According to data from Minet.



    com, omeprazole is the only drug for the treatment of peptic ulcers with sales exceeding 1 billion yuan in Chinese urban physical pharmacy terminals.



    Among the TOP5 varieties in 2020, only omeprazole has maintained a positive growth trend



    .



    The sales growth rate of metoprolol tablets has remained above 10%, and exceeded 3.5 billion yuan in 2020.

    With the new formulations of large varieties entering the centralized procurement again, the varieties covered by the national procurement have become more comprehensive



    .

    03 Nearly 200 pharmaceutical companies meet the conditions, and fierce competition is coming



    On February 17, the Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Launching the Seventh Batch of Nationally Organized Centralized Drug Purchasing Related Drug Information Reporting Work"., 30mg, 40mg, 50mg), etc.208 kinds of medicines



    .

    This centralized procurement also involves a number of over 1 billion varieties, and some of the products have been reviewed by more than 10 companies



    .
    According to the Insight database, a total of 24 companies for omeprazole injection passed the consistency evaluation, a total of 13 pharmaceutical companies for the oral normal-release formulation of tenofovir alafenamide passed the consistency evaluation, and there were also more than 10 companies for clindamycin phosphate injection, etc.
    Enterprise review
    .

    The original research of tenofovir alafenamide oral normal-release dosage form is Gilead, and the companies that have reviewed it include Fujian Guangshengtang Pharmaceutical, Chengdu Yuandong Biopharmaceutical, Kelun, Qilu Pharmaceutical, Chengdu Better, Chia Tai Tianqing Pharmaceutical, etc.

    .

    According to Cyberland, the rules for the first five batches of centralized procurement tend to be stable—the whole country participates, and a maximum of 10 companies are allowed to be selected.
    3 companies, 2 years; 4 companies and above, 3 years), 80% of the agreed procurement volume selected by 4 companies and above (50% from 1 company, 60% from 2 companies, and 70% from 3 companies)
    .

    The domestic patent of tenofovir alafenamide oral normal-release dosage form has expired in July 2021.
    Once the seventh batch of centralized procurement is officially launched, the degree of competition it faces is self-evident
    .

    04 The renewal of the national procurement contract allows price increases, and enterprises usher in new opportunities


    With the gradual advancement of the seventh batch of centralized procurement, the renewal of the previous batches of centralized procurement has also been launched one after another
    .

    On January 24, the Jilin Provincial Drug Procurement Center issued the "Notice on Announcement of the Announcement of the Result of the Bidding Renewal Project of the Selected Drugs in Jilin Province after the Expiry of the First and Third Batch of State-Organized Centralized Drug Purchasing Agreements".
    A total of 16 products participated in the bid renewal.
    , the prices of some drugs have increased significantly, for example, the clozapine tablets of Jiangsu Enhua Pharmaceutical Co., Ltd.
    increased by more than 120%
    .

    It is not a new thing to increase the price of domestically sourced varieties after the renewal of the contract.
    The Shaanxi Provincial Medical Insurance Bureau also proposed that the price of the last round of centralized procurement was low, and due to factors such as rising costs, the company could not continue to supply at the original selected price.
    Allow the selected price to rise appropriately
    .

    For the selected pharmaceutical companies, allowing the renewal of the contract to increase the price is undoubtedly a good opportunity for it
    .

    As we all know, most of the varieties entering the centralized procurement have achieved a considerable decline
    .
    The first five batches of chemical drugs were collected from China, and the average decline was at least 50%, the largest at 59%, and the highest decline was over 90%
    .

    With the dynamic adjustment of centralized procurement prices, to a certain extent, it may stimulate the enthusiasm of enterprises to participate in centralized procurement, and under the premise of maintaining reasonable profit margins, the supply of enterprises will become more and more stable
    .

    Attachment: The seventh batch of domestically-picked varieties of over-evaluation enterprises + specifications (as of February 17, the table is manually sorted, if there are any mistakes, please comment and correct)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.